NEJM: Emapalumab Treatment of Primary Phytophalymplylylymlympercell Cytomegapathy
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Primary phage lymphocytic hyperplasia is a rare disease characterized by immune disorders and high inflammation, usually occurring in infancy, with higher mortality ratesresearchers examined the effectiveness and safety of emapalumab (a human anti-interferon antimon antibody) in combination with dexamethasoneThis study is a Phase II-III study that includes patients with primary phytophalym lymphocyte cytomotic hyperphtication patients who have previously been treated or were not treatedThe main outcome of the study was the overall response, which assessed the patient according to objective clinical and laboratory criteria34 patients (27 previously treated patients and 7 previously untreated patients) received emapalumab and 26 patients completed the studyA total of 63% of patients who had previously been treated and 65% of untreated patients responded after receiving emapalumab treatmentOf those who had previously been treated, 70 per cent were transplantable, while 65 per cent of patients who had received emapalumab alone could be transplantedIn the last follow-up, 74% of patients who had previously been treated and 71% of those who received only emapalumab survivedEmapalumab did not have any organ toxicity, during treatment, 10 patients developed serious infections, and 1 case was discontinued due to spread tissue cytobacteria diseaseresearch, Emapalumab is an effective drug for the treatment of primary phage lymphocytic lymphocytic cell growth
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
